Forward Ventures
Forward Ventures ic a venture capital company that focuses in companies in the area of biological sciences.
Business Model:
Revenue: $18.6M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Forward Ventures Information
Geographic Data
Address: 9255 Towne Centre Drive Suite 350San
City:
State: CA
Zip: 92121
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Forward Ventures, founded in 1993, is a leading life-science venture capital firm located in San Diego. Forward has a team of investment professionals with extensive experience in entrepreneurship, venture capital and operations. Our firm has invested in over 50 companies since it was founded in 1993 and currently has more than $500 million in capital under management. The most recent fund, Forward V, continues Forward Ventures’ program of life sciences and health care venture investing in companies of all stages of development. Forward invests throughout the United States and will consider select European opportunities.
Contact Phone:
+18586776077
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2001 | Acorda Therapeutics | Series A | 0 |
| 7/2007 | TargeGen | Series D | 40M |
| 4/2005 | NovaCardia | Series A | - |
| 9/2006 | NovaCardia | Series B | 48M |
| 3/2003 | Hypnion | Series B | 47.5M |
| 8/2019 | Virtuozo | Seed Round | 0 |
| 11/2022 | Xanadu | Series C | 0 |
| 10/2005 | Nereus Pharmaceuticals | Series D | 0 |
| 2/2010 | Altair Therapeutics | Series B | 17M |
| 11/2002 | Kemia | Series A | 16.5M |
| 12/2000 | Ambit Biosciences | Series B | 18.8M |
| 8/2007 | Nereus Pharmaceuticals | Series D | 0 |
| 11/2007 | Asteres | Series C | 4M |
| 10/2007 | Concurrent Thinking | Venture Round | 3.2M |
| 5/2005 | Ambit Biosciences | Series C | 31M |
| 11/2007 | Viracta Therapeutics | Series A | 20M |
| 4/2002 | Micromet | Series B | 0 |
| 4/2017 | Viracta Therapeutics | Series B | 0 |
| 5/2001 | AGY | Series B | 13M |
| 1/2007 | Proprius Pharmaceuticals | Series A | 0 |
| 1/2005 | Predix Pharmaceuticals | Series C | 0 |
| 9/2003 | NovaCardia | Venture Round | 22M |
| 4/2010 | Viracta Therapeutics | Series B | 12M |
| 9/2005 | TargeGen | Series C | 30M |
| 8/2005 | Adiana | Series D | 23M |
| 2/2010 | Tioga Pharmaceuticals | Venture Round | 18M |
| 5/2002 | TargeGen | Series A | 10M |
| 1/2004 | TargeGen | Series B | 30M |
| 3/2007 | Affinium Pharmaceuticals | Series A | 18M |
| 1/2002 | Gryphon Therapeutics | Series B | 26M |
| 8/2003 | Micromet | Series C | 0 |
| 8/2006 | Kemia | Series C | 0 |
| 8/2011 | Affinium Pharmaceuticals | Series B | 0 |
| 4/2002 | Dynavax Technologies | Series D | 0 |
| 1/1995 | Corixa | Series A | 15M |
| 3/2012 | Viracta Therapeutics | Series B | 0 |
| 11/2003 | Sanarus Medical | Series C | 19.1M |
| 6/2011 | Ambit Biosciences | Series D | 0 |
| 5/2003 | Acorda Therapeutics | Series B | 55.3M |
| 1/2006 | Tioga Pharmaceuticals | Series A | 24M |
| 11/2012 | Ambit Biosciences | Venture Round | 0 |
| 7/2001 | Sanarus Medical | Series B | 13.8M |
| 4/2007 | NovaCardia | Series B | 18M |
| 6/2010 | Nereus Pharmaceuticals | Series E | 0 |
| 9/2007 | Sequel Pharmaceuticals | Series A | 20M |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 4/2004 | Imagine Pharmaceuticals | Series A | 3.7M |
| 9/2013 | Affinium Pharmaceuticals | Debt Financing | 0 |
| 11/2007 | Ambit Biosciences | Series D | 49.3M |
| 3/2004 | Kemia | Series B | 33.5M |
| 9/2003 | Conforma Therapeutics | Series C | 30M |
| 3/2008 | LigoCyte Pharmaceuticals | Series C | 29.5M |
| 10/2006 | Morphotek | Series D | 0 |
| 8/2006 | Cabrellis Pharmaceuticals | Series A | 27.5M |
| 12/2005 | Hypnion | Series B | 0 |
| 2/2004 | Morphotek | Series C | 26M |
| 4/2007 | Syndax Pharmaceuticals | Series A | 40M |
| 3/2010 | Syndax Pharmaceuticals | Series A | 9M |
| 8/2013 | Syndax Pharmaceuticals | Series B | 0 |
| 4/2005 | Sanarus Medical | Series D | 23M |
| 2/2007 | Sanarus Medical | Series E | 15M |
| 3/2000 | Variagenics | Funding Round | 19M |
| 9/2004 | Cellective Therapeutics | Series A | 27.5M |
| 11/2022 | Xanadu | Series C | 0 |
| 8/2019 | Virtuozo | Seed Round | 0 |
| 4/2017 | Viracta Therapeutics | Series B | 0 |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 9/2013 | Affinium Pharmaceuticals | Debt Financing | 0 |
| 8/2013 | Syndax Pharmaceuticals | Series B | 0 |
| 11/2012 | Ambit Biosciences | Venture Round | 0 |
| 3/2012 | Viracta Therapeutics | Series B | 0 |
| 8/2011 | Affinium Pharmaceuticals | Series B | 0 |
| 6/2011 | Ambit Biosciences | Series D | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
